Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why I rate REPL stock a Sell.

Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...